II期临床-话题@MedSci

#II期临床#

478篇内容 | 2552人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524587, encodeId=def0152458e46, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功, objectType=article, longId=67827, objectId=d4666e827af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4666e827af, replyNumber=0, likeNumber=53, createdTime=2016-05-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4666e827af, moduleTitle=消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4666e827af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524586, encodeId=76461524586fc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Diabetes Care：人类胰岛移植完成III期临床根治1型糖尿病已见曙光！, objectType=article, longId=67059, objectId=ec036e059b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec036e059b8, replyNumber=0, likeNumber=27, createdTime=2016-04-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec036e059b8, moduleTitle=Diabetes Care：人类胰岛移植完成III期临床根治1型糖尿病已见曙光！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec036e059b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524585, encodeId=04661524585ae, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功, objectType=article, longId=66979, objectId=0c7b669e992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7b669e992, replyNumber=0, likeNumber=34, createdTime=2016-04-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7b669e992, moduleTitle=乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c7b669e992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524584, encodeId=60a7152458444, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功, objectType=article, longId=66959, objectId=0eb56695937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eb56695937, replyNumber=0, likeNumber=42, createdTime=2016-04-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eb56695937, moduleTitle=百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eb56695937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524583, encodeId=620315245839d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, objectType=article, longId=65585, objectId=4f7365585cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f7365585cc, replyNumber=0, likeNumber=72, createdTime=2016-03-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f7365585cc, moduleTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f7365585cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524582, encodeId=66ab1524582d5, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报, objectType=article, longId=65458, objectId=5736654581e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5736654581e, replyNumber=0, likeNumber=57, createdTime=2016-03-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5736654581e, moduleTitle=苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5736654581e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524581, encodeId=486a152458158, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=灵北启动精神分裂症新药Lu AF35700 III期临床项目, objectType=article, longId=64867, objectId=068c6486e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=068c6486e77, replyNumber=0, likeNumber=55, createdTime=2016-03-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=068c6486e77, moduleTitle=灵北启动精神分裂症新药Lu AF35700 III期临床项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=068c6486e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524580, encodeId=1b861524580ac, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功, objectType=article, longId=63843, objectId=fe1b6384351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe1b6384351, replyNumber=0, likeNumber=87, createdTime=2016-02-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe1b6384351, moduleTitle=超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe1b6384351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524579, encodeId=a1bb15245e985, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, objectType=article, longId=63534, objectId=bde06353427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde06353427, replyNumber=0, likeNumber=59, createdTime=2016-02-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde06353427, moduleTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde06353427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524578, encodeId=afec15245e8df, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验, objectType=article, longId=61125, objectId=30726112531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30726112531, replyNumber=0, likeNumber=55, createdTime=2015-12-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30726112531, moduleTitle=FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30726112531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524577, encodeId=753615245e749, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=IL-6单抗sirukumab进入巨细胞动脉炎III期临床, objectType=article, longId=59801, objectId=6cef59801ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cef59801ea, replyNumber=0, likeNumber=65, createdTime=2015-12-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cef59801ea, moduleTitle=IL-6单抗sirukumab进入巨细胞动脉炎III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cef59801ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524576, encodeId=2a1c15245e6fa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, objectType=article, longId=56022, objectId=21385602249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21385602249, replyNumber=0, likeNumber=35, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21385602249, moduleTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21385602249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524575, encodeId=f54d15245e5e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, objectType=article, longId=56019, objectId=a3645601997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3645601997, replyNumber=0, likeNumber=63, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3645601997, moduleTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3645601997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524574, encodeId=6c5215245e4be, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, objectType=article, longId=56018, objectId=86745601843, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86745601843, replyNumber=0, likeNumber=28, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86745601843, moduleTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86745601843)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, objectType=article, longId=56015, objectId=17c9560153c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17c9560153c, replyNumber=0, likeNumber=56, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17c9560153c, moduleTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17c9560153c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524572, encodeId=a21e15245e235, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, objectType=article, longId=56014, objectId=262d56014f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d56014f0, replyNumber=0, likeNumber=81, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d56014f0, moduleTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262d56014f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524571, encodeId=73d415245e1df, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验, objectType=article, longId=56011, objectId=342c560114a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=342c560114a, replyNumber=0, likeNumber=35, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=342c560114a, moduleTitle=招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=342c560114a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524570, encodeId=c28515245e09c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究, objectType=article, longId=56009, objectId=dfa856009e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa856009e2, replyNumber=0, likeNumber=84, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa856009e2, moduleTitle=招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfa856009e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524569, encodeId=1eb6152456901, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, objectType=article, longId=55957, objectId=68175595eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68175595eff, replyNumber=0, likeNumber=29, createdTime=2015-09-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68175595eff, moduleTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68175595eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524568, encodeId=b04a1524568ab, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, objectType=article, longId=55622, objectId=6995556228c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6995556228c, replyNumber=0, likeNumber=32, createdTime=2015-09-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6995556228c, moduleTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6995556228c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功

2016-05-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Diabetes Care：人类胰岛移植完成III期临床根治1型糖尿病已见曙光！

2016-04-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功

2016-04-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功

2016-04-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点

2016-03-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

苏亚虹医药科技有限公司“APL-1202中国II期临床中期分析结果”在EAU2016慕尼黑年会做现场汇报

2016-03-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

灵北启动精神分裂症新药Lu AF35700 III期临床项目

2016-03-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功

2016-02-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功

2016-02-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验

2015-12-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

IL-6单抗sirukumab进入巨细胞动脉炎III期临床

2015-12-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案

2015-09-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段

2015-09-03

科室
- - 订阅+
  - 更多科室
工具
服务